PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.16%
R&D growth less than half of AVXL's 97.90%. David Dodd would verify if efficiency advantage is sustainable.
23.98%
G&A growth while AVXL reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
7.46%
Other expenses growth less than half of AVXL's 124.81%. David Dodd would verify if advantage is sustainable.
15.26%
Operating expenses growth while AVXL reduces costs. John Neff would investigate differences.
15.26%
Total costs growth while AVXL reduces costs. John Neff would investigate differences.
-36.68%
Both companies reducing interest expense. Martin Whitman would check industry trends.
7.46%
D&A growth while AVXL reduces D&A. John Neff would investigate differences.
-50.67%
EBITDA decline while AVXL shows 44.42% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-15.26%
Operating income decline while AVXL shows 45.10% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-81.62%
Other expenses reduction while AVXL shows 1122.50% growth. Joel Greenblatt would examine advantage.
-50.43%
Pre-tax income decline while AVXL shows 48.42% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-36.68%
Both companies reducing tax expense. Martin Whitman would check patterns.
-50.43%
Net income decline while AVXL shows 48.65% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-43.14%
EPS decline while AVXL shows 51.92% growth. Joel Greenblatt would examine position.
-43.14%
Diluted EPS decline while AVXL shows 51.92% growth. Joel Greenblatt would examine position.
5.01%
Share count reduction below 50% of AVXL's 3.66%. Michael Burry would check for concerns.
5.01%
Diluted share reduction below 50% of AVXL's 3.66%. Michael Burry would check for concerns.